HBM+ has partnered with Daisy Intelligence, an AI-powered risk management platform, to develop a fraud prevention solution tailored to the Group Benefits industry.
Daisy's platform is used to leverage HBM+ data to identify outlier situations at the provider, member, and claim levels for potential situations of fraud or abuse. Using peer analysis, predictive modeling, social network analysis, and rules monitoring, we can identify the outlying situations that may require further investigation.» Learn more about Daisy Intelligence
With innovation in digital health solutions evolving at a rapid pace, HBM+ continues to enhance its position as an industry leader by partnering with PocketPills, Canada’s leading digital pharmacy.
PocketPills manages the full pharmacy experience in a purely digital environment, from discussions with a pharmacist, to refilling prescriptions to ongoing disease management.» Learn more about PocketPills
Maple is Canada’s leading virtual care company, providing Canadians true 24/7 access to physicians online, in less than two minutes. Unlike other virtual care models, Maple is able to connect patients directly to doctors instantly, without the need to speak to a nurse who will determine if you can get granted access to a doctor.» Learn more about Maple
BEACON Digital Therapy
BEACON Digital Therapy
BEACON is an end-to-end workplace mental health program that makes evidence-based mental health support accessible and affordable. BEACON digital therapy begins with a rigorous assessment (with optional diagnosis), followed by triage and Therapist-Assisted Internet Delivered Cognitive Behavioral Therapy. The program was designed based on the extensive clinical experience and evidence-based treatment methodologies of its affiliate, CBT Associates, one of the largest group psychology practices in Canada.» Learn more about BEACON
HBM+ has been studying the impact of pharmacogenomics on patient outcomes for the past several years. Following an groundbreaking study concluded in 2019, we partnered with Genxys, a leading pharmacogenomics testing company, to design the first integrated digital pharmacogenomics product in Canada. Through this product, plan members will have access to a comprehensive pharmacogenomics test as well as an integrated prescribing decision support tool for the patient’s clinicians (pharmacist and physician).
Through a fully digital experience that connects Genxys and HBM+ systems, patients will be able to request the test kit, transfer their full medication history and get access to a powerful TreatGx prescribing decision tool.» Learn more about GenXys